TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) shares were up 35.8% during trading on Monday . The company traded as high as $0.12 and last traded at $0.11. Approximately 22,505 shares changed hands during trading, a decline of 56% from the average daily volume of 51,120 shares. The stock had previously closed at $0.08.
TC Biopharm Stock Up 35.8 %
The firm has a fifty day moving average price of $0.13 and a two-hundred day moving average price of $0.14.
Get TC Biopharm alerts:Institutional Trading of TC Biopharm
A hedge fund recently bought a new stake in TC Biopharm stock. Nantahala Capital Management LLC acquired a new position in TC Biopharm (Holdings) Plc (NASDAQ:TCBPW – Get Rating) in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 235,294 shares of the company's stock, valued at approximately $117,000.
About TC Biopharm
(Get Rating)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its products pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; ImmuniStim, an unmodified cell therapy to treat COVID-19; TCB009 for the GI-tract cancer treatment; and TCB005/TCB006 that are allogeneic co-stimulatory GD-T CAR pre-clinical drug candidates would target antigens expressed on various solid tumor types.
Featured Stories
- Get a free copy of the StockNews.com research report on TC Biopharm (TCBPW)
- This Is Why Penny Stock GreenPower Motor Company Is A Win
- Comcast Sum of All Parts is Producing a Cumulative Effect
- The Greenbrier Companies: All Aboard For High-Yield In 2023
- Coty Stock is on the Comeback Trail
- Splunk Stock is an AI-Powered Enterprise SEIM Play
Receive News & Ratings for TC Biopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TC Biopharm and related companies with MarketBeat.com's FREE daily email newsletter.